Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing
GLEN ALLEN, Va., Sept. 20, 2011 /PRNewswire/ -- Rock Creek Pharmaceuticals, a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), announced that on September 19, 2011 a utility patent application was filed with the Patent and Trademark Office ("PTO"). This utility patent application is based on several previously-filed provisional applications, and it is directed to various products containing anatabine and the administration of anatabine to reduce inflammation. Anatabine has the potential to be particularly useful for nutritional support for disorders involving inflammation that is associated with Nuclear Factor-KappaB (NF-kB) mediated transcription. NF-kB is a transcription factor that operates in cells and participates in the immune response. NF-kB mediated transcription is associated with numerous disorders, including those with inflammatory components, abnormal immune response and/or inappropriate cell proliferation. NF-kB is associated with over 200 inflammatory pathways.
Rock Creek Pharmaceuticals has developed a dietary supplement, Anatabloc™, that contains anatabine citrate as well as Vitamins A & D3, which was launched on August 30. This is the second dietary supplement developed by the company: CigRx®, the first product, was introduced in August, 2010. CigRx® is a non-nicotine, non-tobacco alternative for smokers that reduces the urge to light a cigarette, and it contains both anatabine citrate and yerba mate. It is believed that this combination of dietary ingredients mimics the brain activity that occurs when nicotine is inhaled. It is available for purchase via a dedicated product website (www.cigrx.com) or the Amazon.com purchase portal. CigRx also is available at all CVS-Pharmacy stores in the Richmond, VA area, and in roug